

Table 3: Results on the most common reported adverse events by the included studies.

| Adverse events | Aragona, 2005 | | Han, 2008a | | Han, 2008b | | Muller, 2008 | |
|-------------------------------|-------------------|-------------------|--------------------|--------------------|-------------------|-------------------|---------------------|----------------|
| | <i>Citalopram</i> | <i>Reboxetine</i> | <i>Mirtazapine</i> | <i>Venlafaxine</i> | <i>Fluoxetine</i> | <i>Sertraline</i> | <i>Escitalopram</i> | <i>Placebo</i> |
| Dry mouth | 2 (11.7%) | 9 (50.0%) | 5 (10.0%) | 6 (13.3%) | 3 (10.7%) | 2 (11.8%) | NR | NR |
| Somnolence | 6 (35.3%) | 4 (22.2%) | 4 (8.0%) | 1 (2.2%) | 1 (3.6%) | 3 (17.6%) | NR | NR |
| Insomnia | 4 (23.5%) | 6 (33.3%) | NR | 2 (4.4%) | 2 (7.1%) | NR | 3 (12.0%) | NR |
| Tremor/anxiety | 5 (29.4%) | 4 (22.2%) | NR | NR | NR | NR | NR | NR |
| Tachycardia | 2 (11.7%) | 7 (38.8%) | NR | NR | NR | NR | NR | NR |
| Increased motor activity | 5 (29.4%) | 2 (11.1%) | NR | NR | NR | NR | NR | NR |
| Nausea | 2 (11.7%) | 3 (16.6%) | 2 (4.0%) | 4 (8.9%) | 5 (17.9%) | 3 (17.6%) | 3 (12.0%) | 5 (19.0%) |
| Vomiting | NR | NR | 1 (2.0%) | 2 (4.4%) | 2 (7.1%) | 1 (5.9%) | NR | NR |
| Blurred vision | 2 (11.7%) | 3 (16.6%) | NR | NR | NR | NR | NR | NR |
| Dizziness | 1 (5.8%) | 4 (22.2%) | 3 (6.0%) | 2 (4.4%) | 1 (3.6%) | 2 (11.8%) | NR | 2 (8.0%) |
| Diarrhea | 2 (11.7%) | 1 (5.5%) | NR | NR | NR | NR | 3 (12.0%) | 6 (23.0%) |
| Sweating | NR | 2 (11.1%) | 2 (4.0%) | 1 (2.2%) | 1 (3.6%) | NR | NR | NR |
| Anorexia | NR | NR | 1 (2.0%) | 2 (4.4%) | 3 (10.7%) | 1 (5.9%) | NR | NR |
| Yawning | NR | NR | 3 (6.0%) | NR | NR | NR | NR | NR |
| Headache | NR | NR | 1 (2.0%) | 1 (2.2%) | NR | NR | 9 (36.0%) | 11 (42.0%) |
| Constipation | NR | NR | NR | NR | 1 (3.6%) | 2 (11.8%) | NR | NR |
| Abdominal discomfort | NR | NR | NR | NR | NR | NR | NR | 4 (15.0%) |
| Nasopharyngitis | NR | NR | NR | NR | NR | NR | 4 (16.0%) | 8 (31.0%) |
| Urinary tract infection | NR | NR | NR | NR | NR | NR | 2 (8.0%) | NR |
| Staphylococcal skin infection | NR | NR | NR | NR | NR | NR | 1 (4.0%) | 2 (8.0%) |

Results are presented as n (%). Abbreviations: NR = not reported.